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High-grade inflammation together with its impact on tradi-
tional risk factors and genetic determinants is strongly impli-
cated in the substantially increased risk of cardiovascular
disease (CVD) and mortality experienced by patients with
rheumatoid arthritis (RA) [1–4]. In view of this complexity, it
should not be unexpected that adequate CVD risk assessment
in RA still eludes us to date [5, 6]. This special issue in
this journal was initiated with the aims of further exploring
mechanisms involved in enhanced CVD risk as well as its
optimal stratification and management in patients with RA.
The increased risk of ischemic heart disease, stroke, and
heart failure is well established in RA [7–9]. A. K. Bacani et al.
herein report that there is also a 46% increased incidence
in atrial fibrillation (AF) independent of traditional AF risk
factors amongst RA patients, in a study that included 831
cases and controls. Severe extra-articular disease, multiple
high sedimentation rates, and COX-2 inhibitor use were
associated with AF. This again illustrates the potential role of
nontraditional risk factors in the increased CVD risk associ-
ated with RA.
Janus kinases (JAK) contribute to cytokine production in
RA [10] and are implicated in CVD [11].M. Garćıa-Bermúdez
et al. document that JAK3 gene polymorphisms are not
associated with cardiovascular events comprising ischemic
heart disease, cerebrovascular disease, peripheral arterial
disease, and/or heart failure, in 2136 RA patients; there were
also no relationships between JAK3 gene polymorphisms
and ultrasound determined carotid intima-media thickness
(CIMT) or plaque amongst 539 of the participants. The cur-
rent findings emphasize the need for identifying other gene
polymorphisms implicated in inflammatory pathways, as
potential determinants of CVD in RA. This group of
researchers has previously reported that gene polymorphisms
located within the MHC region as well as variations of genes
outside this region can contribute to CVD in RA [3, 4].
Anti-cyclic citrullinated peptide (anti-CCP) antibodies
are involved in the pathophysiology of RA [12] and are most
useful in diagnosing this disease. M. V.-Del Mercado et al.
show that in 82 RA patients without conventional cardiovas-
cular risk factors, amongst a range of inflammatory markers,
C-reactive protein and anti-CCP concentrations were most
strongly associatedwith CIMTon ultrasound.TheCIMTwas
larger in 45 anti-CCP positive patients compared to the 37
that tested negative and 62 age and sex matched healthy
controls. Indeed, anti-CCP antibodies can also participate in
atherogenesis amongst patients with RA [12].
Juvenile inflammatory arthritis (JIA) is a rarer disease
than RA. Accordingly, data on the impact of JIA on CVD risk
remain limited. E. Jednacz and L. Rutkowska-Sak compared
body composition and cardiovascular risk factors as well as
CIMT in 30 children with JIA and 20 age and sex matched
control subjects. Lower body mass index (BMI) and BMI
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centile andhigher interleukin-6 concentrationswere found in
JIA patients. The former was likely due to increased
catabolism whereas the latter is strongly associated with sur-
rogatemarkers of early atherogenesis in RA [13].Whether the
findings in the present study translate into a larger incidence
of cardiovascular events later in life amongst JIA patients
requires further study.
Adequate traditional cardiovascular risk management is
possible in RA [14] and can further reduce cardiovascular
event rates to a similar extent as in non-RA subjects [15].
However, besides our current insufficient understanding of
CVD mechanisms, inconsistent traditional cardiovascular
risk recording by treating physicians undoubtedly contributes
to the reported lack of reduction in cardiovascular event rates
over the past decades in RA [5]. E. Ikdahl et al. are currently
investigating means to address this shortcoming. Accord-
ingly, they recently established a structured arthritis clinic
(AC). The European League Against Rheumatism (EULAR)
recommendations on CVD risk assessment [5] were imple-
mented and medical secretaries, patients self-reporting on
computer screens, rheumatology nurses, and the treating
physicians are all systematically involved in this undertaking.
They report that the overall rate of CVD risk factor recording
is 23.6% and 59.1% in their regular rheumatology clinic (𝑛 =
612) and AC (𝑛 = 530), respectively. This improvement is
encouraging but still far from optimal and indeed calls for
the implementation of additional innovative strategies, as is
amply discussed by the authors.
An elegant and comprehensive systematic review on the
impact of biologic agents including tumor necrosis factor-𝛼
(TNF-𝛼) blockade with adalimumab, etanercept, or inflix-
imab on lipidmetabolism inRAwas recently reported [16]. In
particular, adalimumab and etanercept can reduce the ath-
erogenic index, that is, the total cholesterol-high density
lipoprotein (HDL) ratio. Importantly also, infliximab use in
RA was shown to enhance HDL antioxidative capacity, an
effect that persisted 6 months after its initiation [17]. N. A.
Rodriguez-Jimenez et al. report on their experience with
etanercept in this regard. Lipid levels were measured at base-
line and 4 and 24 weeks. Whereas this study is observational,
its strength is that only methotrexate (𝑛 = 13) or methotrex-
ate in combination with etanercept (𝑛 = 22) was used as
disease modifying agent therapy. The investigation revealed
that the addition of etanercept tomethotrexate therapy results
in increased HDL concentrations, which may reduce CVD
risk in RA.
Whereas ∼80% of cardiovascular events currently occur
in poor or middle income countries, available CVD risk
assessment strategies were determined based on data that
were obtained in persons that belong to developed popula-
tions [18]. A. Solomon et al. systematically review reported
investigations on CVD risk in African black patients with RA
that belong to a developing population. Such patients were
previously documented to experience marked RA activity
and severity [19]. In relatively large studies, the CVD risk
factor and atherosclerosis burden are now as large in African
black as in white patients with RA despite an earlier epidemi-
ological health transition stage in the former. Adequate CVD
risk management should therefore be performed irrespective
of population origin in RA. Even more strikingly, traditional
CVD risk factors and RA characteristics were consistently
unrelated to atherosclerosis amongst African black patients.
This suggests that there are potential disparities in athero-
genic mechanisms amongst population groups. By contrast,
however, the relations of cardiovascular biomarkers includ-
ing adipokines with atherosclerosis were overall similar in
African black and white patients with RA. Taken together,
these data support the need for population specific cardio-
vascular risk stratification with the consideration of vascular
imaging and, potentially, the use of novel CVD risk biomark-
ers, particularly in African black patients with RA.
The studies reported here have implications in CVD
risk and cardiovascular risk stratification and management
amongst patients with RA and JIA. Equally important, the
evidence reported in this special issue reinforces the need for
more awareness in daily clinical practice of increased cardio-
vascular risk in RA and the notion that much more research
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